Core Viewpoint - The Hainan Free Trade Zone concept is experiencing significant market strength, with multiple companies in the sector seeing substantial stock price increases, particularly 康芝药业 reaching a 20% limit up [1] Company Performance - 康芝药业 has achieved a 20% limit up in stock price [1] - 海汽集团, 海南发展, and 海德股份 also reached limit up [1] - Other companies such as 海南矿业, 海峡股份, 凯撒旅业, and 神农种业 are also experiencing stock price increases [1]

2025年10月27日，康芝药业(300086.SZ)发布2025年三季报。 公司营业总收入为3.26亿元，较去年同报告期营业总收入减少3743.10万元，同比较去年同期下降10.29%。归母净利润为-9661.15万元。经营活动现金净流入 为5717.86万元。 公司最新资产负债率为42.86%，较上季度资产负债率增加1.14个百分点，较去年同期资产负债率增加4.28个百分点。 公司较去年同期总资产周转率持平，同比较去年同期下降1.05%。最新存货周转率为0.86次。 公司股东户数为4.18万户，前十大股东持股数量为1.53亿股，占总股本比例为33.68%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 海南宏氏投资有限公司 | 27.2. | | 2 | 陈惠贞 | 1.79 | | ന | 洪江游 | 1.69 | | 4 | 間英 | 0.53 | | 5 | 洪江涛 | 0.52 | | റ | 朱军 | 0.45 | | 7 | J.P.Morgan Securities PLC-自有资金 | 0.42 | | 8 | JUANL ...

Core Points - The company reported a 30.24% increase in net profit attributable to shareholders after deducting non-recurring gains and losses compared to the same period last year, primarily due to reduced marketing expenses, lower channel maintenance costs, and decreased share-based payment expenses [3] - The net cash flow from operating activities increased by 979.80% year-on-year, mainly due to the receipt of a performance payment of 45 million yuan from the controlling shareholder and a reduction in sales expenses [4] - The company actively fulfilled its social responsibilities by donating medical protective materials and school supplies to disaster-affected areas and local schools [5] Financial Data - The third-quarter financial report was not audited [3][8] - The company did not need to restate previous years' financial data [3] - The company received a total of 110 million yuan in performance payments from its controlling shareholder [6]

康芝药业股份有限公司 2025 年第三季度报告 证券代码：300086 证券简称：康芝药业 公告编号：2025-041 康芝药业股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 康芝药业股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 | | | 本报告期 | 本报告期比上年同 | | 年初至报告 | | --- | --- | --- | --- | --- | --- | | | | | 期增减 | 年初至报告期末 | 期末比上年 | | | | | | | 同期增减 | | 营业收入（元） | | 106,183,265.51 | -26.06% | 3 ...

Core Viewpoint - Kangzhi Pharmaceutical experienced a decline of 5.02% on October 24, with a stock price of 7.19 CNY per share and a total market capitalization of 3.272 billion CNY [1] Company Overview - Kangzhi Pharmaceutical Co., Ltd. is located in Haikou National High-tech Industrial Development Zone, Hainan Province, and was established on January 20, 1994. The company was listed on May 26, 2010 [1] - The main business involves the research, production, and sales of children's medicine, maternal and infant health products, and medical protective equipment, positioning itself as a leading domestic enterprise in children's health [1] - The revenue composition of the main business includes: children's medicine 76.16%, adult medicine 20.89%, and other (supplements) 2.94% [1] Shareholder Information - Noan Fund has a presence among the top ten circulating shareholders of Kangzhi Pharmaceutical, with its Noan Multi-Strategy Mixed A Fund (320016) newly entering the top ten in the second quarter, holding 1.9087 million shares, accounting for 0.43% of circulating shares [2] - The estimated floating loss for the fund today is approximately 725,300 CNY [2] - The Noan Multi-Strategy Mixed A Fund was established on August 9, 2011, with a current scale of 1.399 billion CNY. Year-to-date returns are 67.98%, ranking 251 out of 8,154 in its category; the one-year return is 83.68%, ranking 93 out of 8,025; and since inception, the return is 224.2% [2] Fund Manager Information - The fund managers of Noan Multi-Strategy Mixed A are Kong Xianzheng and Wang Haichang. As of the report, Kong has been in position for 4 years and 333 days, managing a total fund size of 4.607 billion CNY, with the best return during his tenure being 83.16% and the worst being -16.74% [3] - Wang has been in position for 3 years and 95 days, managing a total fund size of 2.529 billion CNY, with the best return during his tenure being 70.27% and the worst being -18.8% [3]

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.19% on October 23, with Shuyou leading the drop [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index also rose by 0.22%, closing at 13025.45 [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - ST Suwu (code: 600200) with a closing price of 1.01, up 5.21% [1] - Lianhuan Pharmaceutical (code: 600513) closed at 21.13, up 4.14% with a trading volume of 344,100 shares and a turnover of 731 million [1] - ST Nuotai (code: 688076) closed at 38.72, up 4.09% with a trading volume of 67,000 shares and a turnover of 258 million [1] - Conversely, significant decliners included: - Buzou Shen (code: 300204) with a closing price of 35.53, down 7.52% [2] - Haichen Pharmaceutical (code: 300584) closed at 51.72, down 7.25% with a trading volume of 83,600 shares and a turnover of 434 million [2] - Xiangrikui (code: 300111) closed at 8.06, down 6.06% with a trading volume of 2,061,600 shares and a turnover of 1.675 billion [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.547 billion from major funds, while retail investors contributed a net inflow of 2.56 billion [2][3] - Key stocks with significant capital flow included: - Lianhuan Pharmaceutical had a net inflow of 65.45 million from major funds, but a net outflow of 55.76 million from retail investors [3] - Kangzhi Pharmaceutical (code: 300086) saw a net inflow of 27.84 million from major funds, with a minor net outflow from retail investors [3] - Huana Pharmaceutical (code: 688799) had a net inflow of 26.15 million from major funds, but also faced outflows from retail investors [3]

证券代码：300086 证券简称：康芝药业 公告编号：2025-040 康芝药业股份有限公司 关于控股股东协议转让公司部分股份完成过户登记的公告 本次协议转让各方保证向本公司提供信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。本公司及董事会全体成员保证信息披露内容 与信息披露义务人提供的信息一致。 特别提示： 1.康芝药业股份有限公司(以下简称"康芝药业"或"公司")控股股东海南宏 氏投资有限公司（以下简称"宏氏投资"）于 2025 年 9 月 9 日与北京晨乐资产管 理有限公司（代表"晨乐佳享 4 号私募证券投资基金"，基金编号：SGP496）（以 下简称"晨乐佳享 4 号"）签署了《海南宏氏投资有限公司与晨乐佳享 4 号关于康 芝药业股份有限公司之 5.0004%股份转让协议》,宏氏投资通过协议转让的方式将 其持有的公司 22,758,000 股无限售流通股（占公司股份总数的 5.0004%）转让给 晨乐佳享 4 号,本次股份协议转让价格为 5.34 元/股，股份转让总价款为人民币 12,152.772 万元。本次股份转让完成后，晨乐佳享 4 号持有公司股份 22,758,000 股 ...

Group 1 - The Hainan Free Trade Zone concept rose by 2.58%, ranking first among concept sectors, with 22 stocks increasing, including Haixia Co., Haima Automobile, and ST Huawen hitting the daily limit [1][2] - Notable gainers included Haikou Group, Hainan Haiyao, and Kangzhi Pharmaceutical, which rose by 6.38%, 6.14%, and 5.69% respectively [1] - The stocks with the largest declines were Hainan Huatie, Junda Co., and *ST Shuangcheng, which fell by 1.30%, 1.23%, and 1.06% respectively [1] Group 2 - The Hainan Free Trade Zone concept saw a net inflow of 358 million yuan from main funds, with 18 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan [2] - The top net inflow stock was Haixia Co., with a net inflow of 108 million yuan, followed by HNA Holding, Hainan Development, and Haide Co. with net inflows of 89.09 million yuan, 82.73 million yuan, and 64.19 million yuan respectively [2][3] - The highest net inflow ratios were seen in Haide Co., ST Huawen, and Hainan Haiyao, with ratios of 14.30%, 13.37%, and 12.49% respectively [3] Group 3 - The top stocks in the Hainan Free Trade Zone concept included Haixia Co. with a daily increase of 10.03% and a turnover rate of 6.55%, followed by HNA Holding with a 1.80% increase and a turnover rate of 2.30% [3][4] - Other notable performers included Hainan Development with a 2.99% increase and a turnover rate of 8.46%, and Haikou Group with a 6.38% increase and a turnover rate of 7.54% [4] - Stocks such as Hainan Huatie and Junda Co. experienced declines of 1.30% and 1.23% respectively, with negative main fund flows [4]

Group 1 - The core viewpoint of the news is that Kangzhi Pharmaceutical has seen a significant increase in its stock price, rising by 5.14% to 7.57 CNY per share, with a trading volume of 427 million CNY and a turnover rate of 13.03%, leading to a total market capitalization of 3.445 billion CNY [1] - Kangzhi Pharmaceutical, established on January 20, 1994, and listed on May 26, 2010, is a leading domestic children's health enterprise in China, focusing on the research, production, and sales of children's medicine, maternal and infant health products, and medical protective equipment [1] - The company's main business revenue composition includes 76.16% from children's medicine, 20.89% from adult medicine, and 2.94% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Kangzhi Pharmaceutical, a fund under Nuoan Fund, specifically Nuoan Multi-Strategy Mixed A (320016), has entered the top ten in the second quarter, holding 1.9087 million shares, which accounts for 0.43% of the circulating shares [2] - The Nuoan Multi-Strategy Mixed A fund has achieved a year-to-date return of 62.9%, ranking 344 out of 8161 in its category, and an annual return of 88.6%, ranking 126 out of 8021 [2] - The fund has been in existence since August 9, 2011, with a total size of 1.399 billion CNY and a cumulative return of 214.4% since its inception [2]

Group 1 - The Chinese medicine concept continues to rise, with Wanbangde hitting the daily limit, and companies such as Kangzhi Pharmaceutical, Tianmu Pharmaceutical, Zhenbaodao, and Jilin Aodong also experiencing gains [1]